Ajouter à une liste

Communiqués Poltreg S.A.

Actions

PTG

PLPLTRG00038

Recherche biotechnologique et médicale

Marché Fermé - Warsaw S.E. 17:55:44 02/10/2026			Varia. 5j.	Varia. 1 janv.
20,30 ^PLN	-0,49%		-4,69%	-17,14%

09/09	Poltreg S.A. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
11/05	Poltreg S.A. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI

Communiqués

11/03	PolTREG poursuit la procédure d’enregistrement au niveau européen de sa thérapie à base de TREG destinée au traitement du diabète de type 1	GL
10/03	PolTREG moves forward with the European registration process for TREG therapy in type 1 diabetes	GL
07/11	Dr. Adrian Bot joins Immuthera to support the company with his unique experience in commercialization of groundbreaking cell therapies	GL
04/08/25	PolTREG Doses First Patient in Phase II Trial for Pre-Symptomatic Type 1 Diabetes with PTG-007	GL
31/07/25	PolTREG and U.S. Subsidiary Immuthera Secure Positive FDA Opinion, Paving the Way for a Registrational Pre-Symptomatic Type 1 Diabetes Trial	GL
04/07/25	Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions	GL
13/06/25	PolTREG Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy	GL
15/05/25	Positive EMA Opinion on Pediatric Investigation Plan for PolTREG’s Treg Therapy in Type 1 Diabetes	GL
24/10/24	PolTREG launches Phase 2 cell therapy trial in children with presymptomatic diabetes	AQ
26/09/24	PolTREG starts preclinical CAR-Treg development for neuroinflammatory autoimmune diseases	AQ
16/09/24	China patent notification boosts PolTREG’s development of Treg cell therapy in multiple sclerosis	AQ
09/09/24	PolTREG Treg cell therapy for patients with type-1 diabetes shows long-term clinical remission and insulin independence	AQ
24/06/24	PolTREG’s type-1 diabetes Treg cell therapy PTG-007 demonstrates long-term safety and efficacy for up to 12 years	AQ
04/04/24	PolTREG identifies promising efficacy biomarker for Type-1 diabetes in patients treated with its Treg therapy in combination with rituximab	AQ
11/03/24	PolTREG receives CGMP certification to produce cell therapies at its state-of-the-art manufacturing site in Poland	AQ
21/02/24	PolTREG appoints Dan Shelly as Chief Business Development Officer	AQ
30/01/24	PolTREG CEO Trzonkowski co-authors peer-reviewed article showing scientific progress in T-reg autoimmune therapy	AQ
16/01/24	PolTREG receives US Patent Office Notice of Allowance for Treg cell therapy to treat Type-1 Diabetes	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Articles Zonebourse Analyses Zonebourse

Filtres

Dès maintenant, trouvez facilement les meilleurs investissements de demain !